<DOC>
	<DOCNO>NCT00030056</DOCNO>
	<brief_summary>This study determine efficacy safety granulocyte-macrophage colony-stimulating factor ( GM-CSF , sargramostim ) administer subcutaneously patient pulmonary alveolar proteinosis ( PAP ) .</brief_summary>
	<brief_title>GM-CSF Patients With Pulmonary Alveolar Proteinosis</brief_title>
	<detailed_description>PAP rare lung disease characterize accumulation surfactant phospholipid protein within lung . There specific pharmacologic therapy PAP current practice lung lavage general anesthesia invasive limitation . Although unknown anti GM-CSF antibody related disease pathogenesis , observation suggest role GM-CSF lung homeostasis well pathogenesis PAP . Patients receive subcutaneous GM-CSF placebo day follow outpatient basis 2 week , 1 , 2 , 3 , 4 , 5 6 month initiation therapy . Clinical response determine dose schedule evaluate symptom score , gas exchange data , chest radiograph . Completion date provide represent completion date grant per OOPD record</detailed_description>
	<mesh_term>Pulmonary Alveolar Proteinosis</mesh_term>
	<criteria>Inclusion criterion : Diagnosis primary idiopathic PAP Creatinine great 2 mg/dL Bilirubin great 2 mg/dL Liver enzymes great 3 time normal Women must use effective method contraception , post menopausal , surgically sterilize Exclusion criterion : Active respiratory infection Active cardiovascular disease ( e.g. , cardiogenic pulmonary edema ) Underlying myeloproliferative disorder leukemia Other secondary cause PAP ( e.g. , occupational exposure silica HIV PCP ) At increase risk side effect GMCSF therapy ( i.e. , rheumatoid arthritis , immune thrombocytopenia , autoimmune thyroiditis ) Previous therapy GMCSF Pregnant nursing Significant renal liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2002</verification_date>
	<keyword>Sargramostim</keyword>
	<keyword>Injections , Subcutaneous</keyword>
</DOC>